A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis

A. Quintás-Cardama, W. Tong, H. Kantarjian, D. Thomas, F. Ravandi, S. Kornblau, T. Manshouri, J. E. Cortes, G. Garcia-Manero, S. Verstovsek

Research output: Contribution to journalArticle

Abstract

Myelofibrosis (MF; primary or post-essential thrombocythemia/ polycythemia vera) is incurable clonal myeloproliferative disorder, with no effective treatment. Epigenetic changes play an important role in cancer pathogenesis through transcriptional silencing of critical tumor suppressor genes. We conducted a phase-II study to evaluate the activity of DNA methyltransferase inhibitor, 5-azacitidine, in patients with MF. Thirty-four patients (76% previously treated) received 5-azacitidine at 75mg/m2 subcutaneously daily for 7 days, every 4 weeks. Twelve (35%) patients had abnormal cytogenetics and 19 (70%) of 27 evaluable patients had JAK2V617F mutation. Responses occurred in 8 (24%) patients after a median of 5 months (range, 3-10). Partial response occurred in 1 (3%) patient (duration 22+ months) and clinical improvement in 7 (21%) patients (median duration 4 months; range, 2-8.5). Myelosuppression was the major adverse effect, with grade 3-4 neutropenia in 10 (29%) patients. Global DNA methylation assessed by the long interspersed nucleotide element (LINE) bisulfite/pyrosequencing assay decreased from 53% pretherapy to 44% on day 14 (P = 0.0014) and returned to 50% at the end of the first 28-day cycle (P = 0.016). 5-azacitidine is relatively well tolerated and results in induction of global hypomethylation in patients with MF, but results in limited clinical activity.

Original languageEnglish (US)
Pages (from-to)965-970
Number of pages6
JournalLeukemia
Volume22
Issue number5
DOIs
StatePublished - May 2008
Externally publishedYes

Fingerprint

Essential Thrombocythemia
Azacitidine
Polycythemia Vera
Primary Myelofibrosis
Long Interspersed Nucleotide Elements
Myeloproliferative Disorders
Methyltransferases
DNA Methylation
Neutropenia
Tumor Suppressor Genes
Epigenomics
Cytogenetics
Mutation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Quintás-Cardama, A., Tong, W., Kantarjian, H., Thomas, D., Ravandi, F., Kornblau, S., ... Verstovsek, S. (2008). A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia, 22(5), 965-970. https://doi.org/10.1038/leu.2008.91

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. / Quintás-Cardama, A.; Tong, W.; Kantarjian, H.; Thomas, D.; Ravandi, F.; Kornblau, S.; Manshouri, T.; Cortes, J. E.; Garcia-Manero, G.; Verstovsek, S.

In: Leukemia, Vol. 22, No. 5, 05.2008, p. 965-970.

Research output: Contribution to journalArticle

Quintás-Cardama, A, Tong, W, Kantarjian, H, Thomas, D, Ravandi, F, Kornblau, S, Manshouri, T, Cortes, JE, Garcia-Manero, G & Verstovsek, S 2008, 'A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis', Leukemia, vol. 22, no. 5, pp. 965-970. https://doi.org/10.1038/leu.2008.91
Quintás-Cardama, A. ; Tong, W. ; Kantarjian, H. ; Thomas, D. ; Ravandi, F. ; Kornblau, S. ; Manshouri, T. ; Cortes, J. E. ; Garcia-Manero, G. ; Verstovsek, S. / A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. In: Leukemia. 2008 ; Vol. 22, No. 5. pp. 965-970.
@article{b5303cf614644a7eb2e437bca8a1019d,
title = "A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis",
abstract = "Myelofibrosis (MF; primary or post-essential thrombocythemia/ polycythemia vera) is incurable clonal myeloproliferative disorder, with no effective treatment. Epigenetic changes play an important role in cancer pathogenesis through transcriptional silencing of critical tumor suppressor genes. We conducted a phase-II study to evaluate the activity of DNA methyltransferase inhibitor, 5-azacitidine, in patients with MF. Thirty-four patients (76{\%} previously treated) received 5-azacitidine at 75mg/m2 subcutaneously daily for 7 days, every 4 weeks. Twelve (35{\%}) patients had abnormal cytogenetics and 19 (70{\%}) of 27 evaluable patients had JAK2V617F mutation. Responses occurred in 8 (24{\%}) patients after a median of 5 months (range, 3-10). Partial response occurred in 1 (3{\%}) patient (duration 22+ months) and clinical improvement in 7 (21{\%}) patients (median duration 4 months; range, 2-8.5). Myelosuppression was the major adverse effect, with grade 3-4 neutropenia in 10 (29{\%}) patients. Global DNA methylation assessed by the long interspersed nucleotide element (LINE) bisulfite/pyrosequencing assay decreased from 53{\%} pretherapy to 44{\%} on day 14 (P = 0.0014) and returned to 50{\%} at the end of the first 28-day cycle (P = 0.016). 5-azacitidine is relatively well tolerated and results in induction of global hypomethylation in patients with MF, but results in limited clinical activity.",
author = "A. Quint{\'a}s-Cardama and W. Tong and H. Kantarjian and D. Thomas and F. Ravandi and S. Kornblau and T. Manshouri and Cortes, {J. E.} and G. Garcia-Manero and S. Verstovsek",
year = "2008",
month = "5",
doi = "10.1038/leu.2008.91",
language = "English (US)",
volume = "22",
pages = "965--970",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis

AU - Quintás-Cardama, A.

AU - Tong, W.

AU - Kantarjian, H.

AU - Thomas, D.

AU - Ravandi, F.

AU - Kornblau, S.

AU - Manshouri, T.

AU - Cortes, J. E.

AU - Garcia-Manero, G.

AU - Verstovsek, S.

PY - 2008/5

Y1 - 2008/5

N2 - Myelofibrosis (MF; primary or post-essential thrombocythemia/ polycythemia vera) is incurable clonal myeloproliferative disorder, with no effective treatment. Epigenetic changes play an important role in cancer pathogenesis through transcriptional silencing of critical tumor suppressor genes. We conducted a phase-II study to evaluate the activity of DNA methyltransferase inhibitor, 5-azacitidine, in patients with MF. Thirty-four patients (76% previously treated) received 5-azacitidine at 75mg/m2 subcutaneously daily for 7 days, every 4 weeks. Twelve (35%) patients had abnormal cytogenetics and 19 (70%) of 27 evaluable patients had JAK2V617F mutation. Responses occurred in 8 (24%) patients after a median of 5 months (range, 3-10). Partial response occurred in 1 (3%) patient (duration 22+ months) and clinical improvement in 7 (21%) patients (median duration 4 months; range, 2-8.5). Myelosuppression was the major adverse effect, with grade 3-4 neutropenia in 10 (29%) patients. Global DNA methylation assessed by the long interspersed nucleotide element (LINE) bisulfite/pyrosequencing assay decreased from 53% pretherapy to 44% on day 14 (P = 0.0014) and returned to 50% at the end of the first 28-day cycle (P = 0.016). 5-azacitidine is relatively well tolerated and results in induction of global hypomethylation in patients with MF, but results in limited clinical activity.

AB - Myelofibrosis (MF; primary or post-essential thrombocythemia/ polycythemia vera) is incurable clonal myeloproliferative disorder, with no effective treatment. Epigenetic changes play an important role in cancer pathogenesis through transcriptional silencing of critical tumor suppressor genes. We conducted a phase-II study to evaluate the activity of DNA methyltransferase inhibitor, 5-azacitidine, in patients with MF. Thirty-four patients (76% previously treated) received 5-azacitidine at 75mg/m2 subcutaneously daily for 7 days, every 4 weeks. Twelve (35%) patients had abnormal cytogenetics and 19 (70%) of 27 evaluable patients had JAK2V617F mutation. Responses occurred in 8 (24%) patients after a median of 5 months (range, 3-10). Partial response occurred in 1 (3%) patient (duration 22+ months) and clinical improvement in 7 (21%) patients (median duration 4 months; range, 2-8.5). Myelosuppression was the major adverse effect, with grade 3-4 neutropenia in 10 (29%) patients. Global DNA methylation assessed by the long interspersed nucleotide element (LINE) bisulfite/pyrosequencing assay decreased from 53% pretherapy to 44% on day 14 (P = 0.0014) and returned to 50% at the end of the first 28-day cycle (P = 0.016). 5-azacitidine is relatively well tolerated and results in induction of global hypomethylation in patients with MF, but results in limited clinical activity.

UR - http://www.scopus.com/inward/record.url?scp=43749117734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43749117734&partnerID=8YFLogxK

U2 - 10.1038/leu.2008.91

DO - 10.1038/leu.2008.91

M3 - Article

C2 - 18385750

AN - SCOPUS:43749117734

VL - 22

SP - 965

EP - 970

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -